More Stories

Informist, Monday, Aug. 10, 2026

 

Please click here to read all liners published on this story

--Gland Pharma Apr-Jun consol net profit INR 3.17 bln
--Analysts saw Gland Pharma Apr-Jun consol net profit at INR 3.13 bln
--Gland Pharma Apr-Jun consol revenue INR 18.00 bln
--Analysts saw Gland Pharma Apr-Jun consol revenue at INR 17.45 bln
--Gland Pharma Apr-Jun consol net profit INR 3.17 bln vs INR 2.15 bln yr ago
--Gland Pharma Apr-Jun consol revenue INR 18.00 bln vs INR 15.06 bln yr ago
--Gland Pharma consol Apr-Jun EBITDA INR 4.93 bln vs INR 3.68 bln year ago
--Gland Pharma consol Apr-Jun EBITDA margin 27% vs 24% year ago
--Gland Pharma Apr-Jun consol R&D expense INR 772 mln vs INR 664 mln year ago
--Gland Pharma Q1 contract manufacturing revenue INR 8.92 bln, up 20% YoY
--Gland Pharma Q1 business-to-business segment sales INR 9.09 bln, up 19% YoY
--Gland Pharma Apr-Jun revenue from US INR 9.81 bln, up 32% on year
--Gland Pharma Apr-Jun revenue from Europe INR 3.95 bln, up 20% on year
--Gland Pharma Q1 rest of the world mkt sales INR 3.04 bln, up 2% on year

 

By Narayana Krishna

 

HYDERABAD - Execution of projects in its contract development and manufacturing organisation business and healthy growth in US sales helped Gland Pharma Ltd. to meet the Street's expectation for its June quarter earnings.

 

The company reported a consolidated net profit of INR 3.17 billion for the June quarter, up 47% on year but down over 13% on quarter. Revenue from operations for the quarter was up nearly 20% on year and 3% on quarter at INR 18 billion. Analysts had expected Gland Pharma's June quarter net profit to be INR 3.13 billion on revenues of INR 17.45 billion.

 

"Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix," the company said in a press release, quoting Executive Chairman Srinivas Sadu. "We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth."

 

Gland Pharma reported 20% year-on-year rise in its CDMO business revenue for the June quarter to INR 8.92 billion. The US sales for the quarter were up 32% on year at INR 9.81 billion.

 

Gland Pharma reported 19% year-on-year rise in revenue from its business-to-business segment to INR 9.09 billion. This segment accounts for nearly 50% of the company's total revenue. The contract development and manufacturing organisation accounts for the other half.

 

Revenue from Europe, a key market for the company, grew 20% on year to INR 3.95 billion. Revenue from the "rest of the world" markets for the June quarter rose 2% on year to INR 3.04 billion.

 

Gland Pharma reported an improvement of nearly 300 basis points in its earnings before interest, tax, depreciation, and amortisation margin for the June quarter to 27% against 24% a year ago. Analysts had expected the company's EBITDA margin to be in the 24.9-31.8% range. EBITDA for the quarter was INR 4.93 billion, up 34% on year. The company's EBITDA had been estimated at INR 4.6 billion.

 

The company's total expenses for the quarter rose 14% on year to INR 14.27 billion while other expenses were up 14.5% at nearly INR 1.9 billion. Input costs for the quarter were up 5.5% on year at INR 5.9 billion.

 

Gland Pharma spent INR 772 million on research and development in the June quarter against INR 664 million in the year-ago quarter. Monday, its shares ended at INR 2,667.30 on the National Stock Exchange, up 2.6% from Friday's close.  End

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.